3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

TREATMENT WITH GROWTH HORMONE LEADS TO IMPROVEMENT IN TOTAL AND NAïVE CD4 LYMPHOCYTE RECOVERY IN HIV-INFECTED SUBJECTS WITH INCOMPLETE IMMUNE RECONSTITUTION ON HAART

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuOa0203

Smith K.¹, Wang R.², Bosch R.², Margolis D.³, Tenorio A.¹, Pollard R.⁴, Stocker V.⁵, Gross B.⁶, Frances I.⁶, Muurahainen N.⁷, ACTG 5174 Protocol Team A.^5
1Rush University Medical Center, Chicago, United States of America, ²Harvard School of Public Health, Boston, United States of America, ³UT Southwestern Medical Center, Dallas, United States of America, ⁴UC Davis Medical Center, San Diego, United States of America, ⁵AACTG Operations Center, Silver Spring, United States of America, ⁶University of Michigan, Ann Arbor, United States of America, ⁷Serono, Inc, Rockland, United States of America

OBJECTIVES: To evaluate the immunologic effects of recombinant growth hormone (rGH) on HIV+ subjects with incomplete immune reconstitution on HAART.

METHODS: Sixty subjects on HAART were randomized to receive rGH 1.5mg SC QD +HAART for 48 weeks (ARM A) or continue HAART alone for 24 wks followed by addition of rGH 3.0 mg SC QD for 24 wks (ARM B). Eleven subjects in ARM A underwent thymus CT scans at baseline and wk 24 to evaluate thymus size. Statistical comparisons were made using Wilcoxon signed-rank.

RESULTS: All subjects had been on HAART for > 1 year, entry CD4<350 and VL<400 and maintained VL <400 c/ml through week 48. Baseline median total CD4 for ARM A and B were 223 and 219, respectively. Six subjects went off study prior to week 48. Arm A trended toward increases in total (p=0.054) and naïve (p=0.099) CD4 cell count from baseline to week 24 while ARM B had no significant change. By wk 48, both arms had significant increases in total and naïve CD4 cells. From baseline to week 48, median change in total and naïve CD4 for ARM A and B were +36, +26 and +55, +23 respectively (p< 0.002 for each). In ARM B, the median change in naïve CD4 # from BL to wk 24 (HAART alone) was 5, the change from wk 24 to 48 (HAART + rGH) was 24, (median difference in changes: 24; p<0.001). Seven of 11 (64%) in ARM A had increased thymus size from baseline to week 24 (p=0.06).

CONCLUSIONS: Treatment with rGH is associated with significant increases in total and naïve CD4 count compared to HAART alone. Treatment with rGH is associated with an increase in thymus size. This is the first randomized clinical trial to demonstrate immunologic effects of rGH combined with HAART.

Download PDF of this abstract.

050724
Clinical | TuOa0203 | Kimberly Smith
New antiretroviral agents

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.